Dipraglurant, aslo known as ADX-48621, is a negative allosteric modulator of the mGlu5 receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID).
For research use only. We do not sell to patients.
| Name | Dipraglurant |
|---|---|
| Iupac Chemical Name | 6-Fluoro-2-[4-(2-pyridinyl)-3-butyn-1-yl]imidazo[1,2-a]pyridine |
| Synonyms | ADX-48621; ADX48621; ADX 48621; Dipraglurant |
| Molecular Formula | C16H12FN3 |
| Molecular Weight | 265.2914 |
| Smile | FC1=CN2C(C=C1)=NC(CCC#CC3=NC=CC=C3)=C2 |
| InChiKey | LZXMUJCJAWVHPZ-UHFFFAOYSA-N |
| InChi | InChI=1S/C16H12FN3/c17-13-8-9-16-19-15(12-20(16)11-13)7-2-1-5-14-6-3-4-10-18-14/h3-4,6,8-12H,2,7H2 |
| CAS Number | 872363-17-2 |
| Related CAS |
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | Off-white solid to white solid |
|---|---|
| Purity | >98% |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Solubility | Soluble in DMSO |
| Handling | |
| Shipping Condition | Shipped under ambient temperature |
| HS Code |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |